Dr. Steven Fishbane MD
Chief of Nephrology, Medical Director, Winthrop University Hospital
Member of the Healthcare Council
Council Member Biography
Steven Fishbane, MD, is Chief of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease Research at Winthrop-University Hospital (WUH) in Mineola, NY. Dr. Fishbane is also Professor of Medicine at the New York State University at Stony Brook School of Medicine and Medical Director of the Dialysis Network, a group of WUH-affiliated inpatient and outpatient dialysis centers. Renowned for his studies on end-stage renal disease and dialysis therapy, Dr. Fishbane is also a member of the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-KDOQI), which develops guidelines for the treatment of anemia associated with chronic kidney disease. Dr. Fishbane is on the Editorial Board for the Journal of the American Society of Nephrology and Advances in Renal Replacement and is a reviewer for several journals, including the New England Journal of Medicine. (This is me - Update Profile)
Employment History
- 2005 - Unspecified
- Chief of Nephrology, Medical Director, Winthrop University Hospital
- 1993 - Unspecified
- Professor of Medicine, Stony Brook University - CC
GLG NewsSM Analyses by Steven Fishbane
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Amgen, ESA Safety in Oncology, and FDA's ODAC Panel
March 3, 2008
Anemia Drugs Raise Death Risk for Cancer Patients | blogs.wsj.com
1- This analysis adds to the formalized analysis of the safety literature on ESA use in oncology. 2- Its timing will impact on the FDA CDER ODAC meeting scheduled to review Amgen and Ortho Biotech's ESA drugs.
-
FDA Panel of Injectafer Safety, Impact for Galenica and AMAG
January 28, 2008
Galenica in 2007: a new record year for strategy and business | www.galenica.com
1- Raises the upcoming FDA safety meeting on Injectafer (Ferinject). 2- Issues related to hypophosphatemia and cardiovascular health raised. 3- Quaestion of impact for ferumoxytol (AMAG) and other IV iron drugs.
GLG Study Groups with Steven Fishbane(?)
| Study Group Name | No. Members |
|---|---|
| Nephrologists (US) | 538 |
| Attending-level Nephrologists (US) | 268 |
| Attending-level Nephrologists in the US who are in GLG Member Programs | 151 |
| Physicians who Treat End Stage Renal Disease (ESRD) | 150 |
| Aranesp Prescribers (US) | 85 |
GLG Live Meetings with Steven Fishbane(?)
Recent Seminars
-
November 2, 2007 | San Francisco
GLGi: Chronic Kidney Disease Treatment Guidelines -
September 19, 2007 | Boston
GLGi: Chronic Kidney Disease Treatment Guidelines
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.